Biblio Discovery — Demo Discovery Service

7 hasil untuk "Shingpan Chan"

Menampilkan 1–7 · 0,62 detik · RSS

  1. Artikel Jurnal

    GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo

    Kaili Jiang; Xia Tang; Jing Guo dkk.

    Cancer Medicine, Vol. 10 No. 14 · 2021 · Inggris · DOAJ Scopus

    Abstract Abnormallyactivated FGFR1 has been validated as a therapeutic target for differentcancers. Although a variety of FGFR inhibitors have shown benefit in manyclinical patients with FGFR1 aberration, FGFR1 mutant resistance such as V561Mmutation, has been reported. To date however, no FGFR…

  2. Artikel Jurnal

    GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo

    Yuting Wang; Lenghe Zhang; Xia Tang dkk.

    Translational Oncology, Vol. 13 No. 4 · 2020 · Inggris · DOAJ Scopus

    GZD824 is a novel third-generation BCR-ABL inhibitor. It entered Phase II clinical trials in China and Phase Ib clinical trials in USA in 2019 for treatment of patients with resistant chronic myeloid leukemia (CML). We found that at concentrations below 10 nM, GZD824 significantly suppresses FLT3…

  3. Artikel Jurnal Teks lengkap

    JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

    Jie Wang; Yang Zhou; Xia Tang dkk.

    Molecules, Vol. 27 No. 19 · 2022 · Inggris · DOAJ Scopus

    The tropomyosin receptor kinases (TRKs) have been validated as effective targets in anticancer drug discovery. Two first-generation TRK inhibitors have been approved into market and displayed an encouraging therapeutic response in cancer patients harboring TRK fusion proteins. However, acquired…

  4. Artikel Jurnal

    Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

    Tao Zhang; Rong Qu; Shingpan Chan dkk.

    Molecular Cancer, Vol. 19 No. 1 · 2020 · Inggris · DOAJ Scopus

    Abstract Background Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFR T790M mutation. The discovery of third-generation EGFR…

  5. Artikel Jurnal

    ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

    Peiran Song; Gang Bai; Shingpan Chan dkk.

    Frontiers in Pharmacology, Vol. 13 · 2022 · Inggris · DOAJ Scopus

    Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2-inducible T cell kinase are critical targets…